Thus, since the accumulation of a mutant p53 in cancer cells can be responsible for chemoresistance, it cannot be excluded that the observed cell sensitivity to PRIMA-1Met in mutant p53 carrying cells is partially related to mutant p53 protein reduction. The gene discussed is TP53; the disease is cancer.